首页 | 本学科首页   官方微博 | 高级检索  
检索        

阿托伐他汀对糖尿病肾病合并冠心病患者的肾脏保护作用研 究
引用本文:李小慧,赵晓云.阿托伐他汀对糖尿病肾病合并冠心病患者的肾脏保护作用研 究[J].中国医药导报,2014(5):78-80.
作者姓名:李小慧  赵晓云
作者单位:[1] 河北省平山县人民医院内科,河北平山,050400 [2] 河北省人民医院检验科,河北石家庄,050051
摘    要:目的 探讨阿托伐他汀对糖尿病肾病合并冠心病患者的肾脏保护作用.方法 选择河北省平山县人民医院2012年1月~2013年4月收治的71例糖尿病肾病合并冠心病患者作为研究对象,对照组35例采用常规治疗,观察组36例加用阿托伐他汀治疗,比较治疗前后患者的血糖、血脂水平以肾功能指标的变化情况,观察指标为空腹血糖(FBG)、餐后2h血糖(2 h PG)、血清胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)以及血清肌酐(Scr)、尿白蛋白排出率(UAER)、尿微量白蛋白(mALB).结果 治疗后两组患者的血糖均控制在正常水平,组间差异无统计学意义(P>0.05);治疗后两组TC、TG、LDL-C、UAER均有明显降低,mALB明显升高,观察组改善更为明显,组间差异有统计学意义(P<0.05).结论 阿托伐他汀对糖尿病肾病合并冠心病患者具有显著的肾脏保护作用,能够延缓肾损害的发展过程,有助于提高患者的生存质量.

关 键 词:糖尿病肾病  冠心痛  阿托伐他汀  血糖  血脂  肾功能

Study on the renal protective effect of Atorvastatin on patients with diabetic nephropathy and coronary heart disease
Institution:LI Xiaohui ZHA Xiaoyun2A 1.Department of Internal Medicine, the People's Hospital of Pingshan County, Hebei Province, Pingshan 050400, China; 2.Department of Laboratory, the People's Hospital of Hebei Province, Shijiazhuang 050051, China
Abstract:Objective To investigate the renal protective effect of Atorvastatin on patients with diabetic nephropathy and coronary heart disease. Methods From January 2012 to April 2013 in the Peoplels Hospital of Pingshan County, Hebei Province, 71 patients with diabetic nephropathy and coronary heart disease were selected as research subjects, 35 patients of the control group were treated with conventional therapy, 36 patients of the observation group were added Atorvastatin, the blood glucose, blood lipid levels and renal function of two groups before and after treatment were com pared, the observed indicators were fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h PG), serum choles terol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C, high density lipoprotein cholesterol (HDL-C) and serum creatiniue (Scr), urinary albumin excretion rate (UAER), urinary albumin (mALB). Results After treatment, the patient's blood glucose levels were controlled in the normal, the difference was not statistically significant between two groups (P 〉 0.05); after treatment, the TC, TG, LDL-C, UAER of two groups were significantly lower, mALB signif icantly increased, and the observation group improved more obviously, the differences were statistically significant be tween the two groups (P 〈 0.05). Conclusion Atorvastatin on patients with diabetic nephropathy and coronary heart disease has a significant protective effect of kidney, and can delay the development of renal damage, which helps to im prove the quality of life of patients.
Keywords:Diabetic nephropathy  Coronary heart disease  Atorvastatin  Blood glucose  Blood lipid  Renal function
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号